Latest Impairment News

Fletcher Building unveiled a comprehensive strategic review and FY25 outlook at its Investor Day, highlighting a focus on manufacturing and distribution alongside significant restructuring costs. The company targets a leaner operation with disciplined capital management and a net debt goal of NZD 400m to 900m.

Metcash Limited reported an 8.9% rise in FY25 sales revenue to $17.3 billion and an 8.6% increase in underlying EBITDA, driven by strong Food pillar growth and the acquisition of Superior Foods. However, declines in Liquor and Hardware EBIT tempered overall profit growth.

Orthocell’s new study confirms Remplir™ delivers superior nerve regeneration and faster muscle recovery compared to traditional sutures, bolstering its US market rollout plans.

Clean Seas Seafood updates shareholders on a revised equity conversion ratio for the Yumbah scrip alternative following significant impairment charges by Yumbah Aquaculture. The scheme meeting is now set for 8 July 2025.

Clean Seas Seafood updates shareholders on a lower scrip alternative ratio following Yumbah Aquaculture’s significant asset impairments, while the scheme meeting is postponed to early July.

Syntara Limited is set to reveal fresh interim results from its Phase 2 trial of SNT-5505, targeting myelofibrosis, during an investor webinar ahead of a major European hematology conference.

Syntara Limited’s lead drug candidate SNT-5505 has secured FDA Fast Track designation, expediting its development for treating myelofibrosis, a rare and serious blood cancer with limited therapies.

Firebrick Pharma has published its pivotal Phase 3 trial results for Nasodine nasal spray, confirming its effectiveness and safety in treating the common cold, especially when used early.

PainChek has advanced its US regulatory approval process with a positive FDA meeting, setting the stage for a potential market debut of its pain assessment app in late 2025.

QuickFee Limited reports mixed Q4 FY25 results with solid growth in US Pay Now and Australian Finance, offset by a significant US Finance decline due to credit impairment. The company completes a major refinancing and capital raise while maintaining FY25 earnings guidance.

QuickFee Limited has launched a A$1.5 million capital raising to fund expansion of its loan books in the US and Australia, following a quarter of record revenue and positive earnings before tax. The fintech also completed a major refinancing and revised its earnings guidance due to a credit impairment provision.

ikeGPS Group Limited reported a robust 48% growth in annual subscription revenue exit run rate for FY25, alongside improved margins and a narrowed EBITDA loss. Despite a lucrative NZ$1 per share acquisition approach, the company declined the offer, confident in its growth trajectory.